Anticoagulant therapy for osteonecrosis associated with heritable hypofibrinolysis and thrombophilia

Expert Opinion on Investigational Drugs

Volumn 10, Issue 7, 2001, Pages 1309-1316

  Glueck, C J ^a   Freiberg, R A ^a   Fontaine, R N ^a   Sieve Smith, L ^a   Wang, P ^a  

^a Cholesterol Center   (United States)

Author keywords

Anabolic androgenic steroids; Enoxaparin; Hip; Hypofibrinolysis; Jaw; Legg Perthes disease; Low molecular weight heparin; MRI; Osteonecrosis; PAI Fx; Plasminogen activator inhibitor activity; Stanozolol; Thrombophilia

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; STANOZOLOL; WARFARIN;

ACNE; ARTERY BLOOD FLOW; BLOOD CLOTTING DISORDER; BONE BLOOD FLOW; CONTROLLED STUDY; DISEASE ASSOCIATION; EDEMA; EPISTAXIS; FEMALE; FEMUR HEAD NECROSIS; FIBRINOLYSIS; HIRSUTISM; HUMAN; HYPOXIA; MALE; REVIEW; THROMBOPHILIA; TOTAL HIP PROSTHESIS; VEIN THROMBOSIS; VENOUS PRESSURE; WEIGHT GAIN;

ANTICOAGULANTS; FIBRINOLYSIS; OSTEONECROSIS; THROMBOPHILIA; TREATMENT OUTCOME;

EID: 0034929637     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.7.1309     Document Type: Review

References (79)

1. Diagnosis of primary femur head osteonecrosis at stage 1 (preradiologic stage)
2. The role of core decompression of osteonecrosis of the femoral head. AOA International Symposium on Osteonecrosis
3. Success of core decompression in the management of early stages of avascular necrosis: A four year prospective study
4. Osteonecrosis of the femoral head: A prospective randomized treatment protocol
5. Treatment of osteonecrosis of the femoral head by core decompression, bone grafting, and electrical stimulation. AOA International Symposium on Osteonecrosis
6. Transtrochanteric rotational osteotomy for osteonecrosis of the femoral head with preoperative superselective angiography
7. Multicenter experience with free vascularized fibular grafts for osteonecrosis of the femoral head
8. Preventing collapse in early osteonecrosis of the femoral head: A randomized clinical trial of core decompression
9. Osteonecrosis: Natural course and conservative therapy
10. Enoxaparin: A new therapy for osteonecrosis associated with heritable hypofibrinolysis and/or thrombophilia
11. Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein (a), and therapy with stanozolol
12. A Preliminary pilot study of treatment of thrombophilia and hypofibrinolysis and amelioration of the pain of osteonecrosis of the jaws
13. Total hip arthroplasty in patients with avascular necrosis of the femoral head: A 2- to 10-year follow-up
14. Total hip arthroplasty in patients with osteonecrosis. The effect of cement techniques
15. Uncemented total hip arthroplasty in osteonecrosis: A 2- to 10-year evaluation
16. Hypofibrinolysis, thrombophilia, osteonecrosis
17. Elevated levels of lipoprotein (a) in familial bone marrow edema syndrome of the hip
18. Thrombophilia due to protein C deficiency, protein S deficiency or resistance to activated protein C as a cause of Legg-Perthes disease
19. Resistance to activated protein C and Legg-Perthes
20. Association of antithrombotic factor deficiencies and hypofibrinolysis with Legg-Perthes
21. The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis
22. Secondhand smoke, hypofibrinolysis, Legg-Perthes disease
23. Hypofibrinolysis: A common, major cause of osteonecrosis
24. Thrombophilia and hypofibrinolysis: Reversible pathogenetic etiologies of osteonecrosis in adults and in children (Legg-Perthes Disease). AOA International Symposium on Osteonecrosis
25. Thrombophilia and hypofibrinolysis: Pathoetiologies of osteonecrosis
26. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis?
27. Familial idiopathic osteonecrosis mediated by familial hypofibrinolysis with high levels of plasminogen activator inhibitor
28. Legg-Perthes disease in three siblings, 2 heterozygous and 1 homozygous for the Factor V Leiden Mutation
29. Risk factors potentially activating intravascular coagulation and causing nontraumatic osteonecrosis
30. Coagulopathies and osteonecrosis
31. Anticardiolipin antibodies and osteonecrosis of the femoral head
32. Hypercoagulability and osteonecrosis. AOA International Symposium on Osteonecrosis
33. Risk factors for osteonecrosis in systemic lupus erythematosus
34. Avascular necrosis of bone in systemic lupus erythematosus: Possible role of haemostatic abnormalities
35. Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system
36. Familial heterozygous protein S deficiency in a patient who had multifocal osteonecrosis
37. The etiology of osteonecrosis. Role of coagulopathies
38. Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip
39. Hypercoagulability and hypofibrinolysis in primary osteoarthritis
40. Thrombophilia, hypofibrinolysis, and alveolar osteonecrosis of the jaw
41. Heterozygosity for the Leiden mutation of the Factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens
42. Exogenous estrogen may exacerbate thrombophilia, impair bone healing, and contribute to development of chronic facial pain
43. Plasminogen activator inhibitor-1 promotor 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography
44. Non traumatic necrosis of the femoral head
45. The pathophysiology of alveolar osteonecrosis of the jaw: Anticardiolipin antibodies, thrombophilia, and hypofibrinolysis
46. Inherited risk factors for thrombophilia among children with Legg-Calve'-Perthes Disease
47. Does thrombophilia play an aetiological role in Legg-Calve-Perthes disease?
48. Perthes' disease and the relevance of thrombophilia
49. Myocardial infarction in a 35 year old man with homocysteinemia, high plasminogen activator inhibitor activity, and resistance to activated protein C
50. Amelioration of osteonecrosis by treatment of thrombophilia and hypofibrinolysis
51. Sieve-Smith: Amelioration of Osteonecrosis by treatment of thrombophilia and hypofibrinolysis
52. Osteonecrosis, medical management
53. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and plasminogen activator inhibitor-1 levels in children and adults
54. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives
55. Sensitivity, specificity, and predictive value of modified assays for activated protein C resistance in children
56. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: A multicenter collaborative family study
57. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasmingen activator inhibitor-1 activity
58. Vitamin supplementation reduces blood homocysteine levels: A controlled trial in patients with venous thrombosis and healthy volunteers
59. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
60. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
61. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the Factor V Leiden Mutation (Resistance to Activated Protein C)
62. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
63. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: A family study with part of the Stanislas Cohort
64. Regulation of PAI-1 gene expression in vivo
65. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and prothrombin A 20210 mutation
66. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives
67. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
68. Thrombophilias: Diagnosis and treatment of thrombophilia relating to contraception and pregnancy
69. Thrombosis in the young; epidemiology and risk factors. A focus on venous thrombosis
70. Venous thrombosis: A multicausal disease
71. Heritable thrombophilia and hypofibrinolysis
72. Incidence of thromboembolism in families with inherited thrombophilia
73. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
74. Relationships between lipoprotein (a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer
75. Plasminogen activator inhibitor activity: An independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome
76. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome
77. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis
78. Interaction of heritable and estrogen-induced thrombophilia: Possible etiologies for ischemic optic neuropathy and ischemic stroke
79. Genetic hypofibrinolysis in complicated pregnancies